Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elite PharmaceuticalsELTP -1.22%60 Days Sales Outstanding is 155.34 as of Jun. 2026, which is 202% above its 10-year median of 51.42. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.52 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 947 Drug Manufacturers companies, Elite Pharmaceuticals ranks worse than 82.47% on this metric.
Elite Pharmaceuticals (OTCPK:ELTP) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Elite Pharmaceuticals Days Sales Outstanding Related Terms
Elite Pharmaceuticals Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elite Pharmaceuticals Days Sales Outstanding Chart
ELTP vs EBS, ANIK, AKBA: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's Days Sales Outstanding falls into.
Elite Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 155.34 mean?
Elite Pharmaceuticals (ELTP) has a Days Sales Outstanding of 155.34 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Elite Pharmaceuticals and its competitors. This is 202% above median its historical median of 51.42. Over the past decade, Elite Pharmaceuticals' Days Sales Outstanding has ranged from 32.88 to 122.06. According to the industry distribution chart, Elite Pharmaceuticals ranks #781 out of 947 companies in the Drug Manufacturers industry, placing it in the top 82.5%.
Is Elite Pharmaceuticals' Days Sales Outstanding too high?
Elite Pharmaceuticals' current Days Sales Outstanding of 155.34 is 202% above median its 10-year median of 51.42. Over the past 10 years, this metric has ranged from a low of 32.88 to a high of 122.06. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Elite Pharmaceuticals' value of 155.34 is 115.8% above this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #781 out of 947 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Days Sales Outstanding compare to EBS and ANIK?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #781 out of 947 companies for Days Sales Outstanding. This places Elite Pharmaceuticals in the lower half of its industry. The industry median Days Sales Outstanding is 71.98. Elite Pharmaceuticals' value of 155.34 is 115.8% above this benchmark. Historically, Elite Pharmaceuticals' own Days Sales Outstanding has ranged from 32.88 to 122.06 over the past decade. While the company's 10-year median is 51.42 vs. the industry median of 71.98, Elite Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current Days Sales Outstanding of 155.34 is 115.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current Days Sales Outstanding is 155.34, which is 202% above median its own 10-year median of 51.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.52, compared to a current price of $0.26 — trading 50% below its estimated fair value. The current Days Sales Outstanding is 155.34, which is 202% above median its 10-year median of 51.42 and 115.8% above the Drug Manufacturers industry median of 71.98. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Days Sales Outstanding is 155.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.26 is trading 50% below its estimated GF Value™ of $0.52.
GuruFocus considers Elite Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ELTP:
Days Sales Outstanding: 155.34 (202% above median its 10-year median of 51.42)
GF Value™: $0.52 vs. price of $0.26 (50% below fair value)
Industry Position: 115.8% above the Drug Manufacturers median (#781 of 947)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score
Get the complete analysis for ELTP
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
